AGIO · Categories · Form 4
AGIO - SEC Form 4 insider transactions
Agios Pharmaceuticals Inc. (AGIO) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for AGIO
- SEC Form 4 filed by Burns James William4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Gheuens Sarah4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Jones Cecilia4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Milanova Tsveta4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Goff Brian4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Corp Dev & Strategy Viswanadhan Krishnan sold $82,260 worth of shares (2,959 units at $27.80) and converted options into 8,100 shares (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Principal Accounting Officer Washburn Theodore James Jr. sold $152,255 worth of shares (5,272 units at $28.88), decreasing direct ownership by 86% to 868 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah converted options into 13,666 shares and sold $117,433 worth of shares (4,055 units at $28.96), increasing direct ownership by 15% to 74,406 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Executive Officer Goff Brian converted options into 39,500 shares and sold $522,873 worth of shares (18,055 units at $28.96), increasing direct ownership by 15% to 164,548 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Legal Officer Burns James William converted options into 17,586 shares and sold $151,113 worth of shares (5,218 units at $28.96), increasing direct ownership by 39% to 44,086 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Principal Accounting Officer Washburn Theodore James Jr. sold $64,378 worth of shares (2,223 units at $28.96) and converted options into 7,495 shares, increasing direct ownership by 551% to 6,140 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Commercial Officer Milanova Tsveta converted options into 9,666 shares and sold $83,057 worth of shares (2,868 units at $28.96), increasing direct ownership by 20% to 41,591 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Financial Officer Jones Cecilia converted options into 16,969 shares and sold $145,814 worth of shares (5,035 units at $28.96), increasing direct ownership by 32% to 49,328 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Chief Corp Dev & Strategy Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Commercial Officer Milanova Tsveta converted options into 8,475 shares and sold $77,601 worth of shares (2,872 units at $27.02), increasing direct ownership by 19% to 34,793 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Legal Officer Burns James William converted options into 6,000 shares and sold $79,428 worth of shares (2,932 units at $27.09), increasing direct ownership by 11% to 31,718 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Executive Officer Goff Brian converted options into 38,278 shares and sold $506,664 worth of shares (18,703 units at $27.09), increasing direct ownership by 16% to 143,103 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah sold $79,428 worth of shares (2,932 units at $27.09) and converted options into 6,000 shares, increasing direct ownership by 5% to 64,795 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Commercial Officer Milanova Tsveta converted options into 6,000 shares and sold $79,428 worth of shares (2,932 units at $27.09), increasing direct ownership by 12% to 29,190 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Financial Officer Jones Cecilia converted options into 6,000 shares and sold $79,428 worth of shares (2,932 units at $27.09), increasing direct ownership by 9% to 37,394 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,768 worth of shares (200 units at $43.84) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah exercised 2,454 shares at a strike of $25.01 and sold $107,436 worth of shares (2,454 units at $43.78) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah exercised 200 shares at a strike of $25.01 and sold $8,762 worth of shares (200 units at $43.81) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah exercised 3,302 shares at a strike of $25.01 and sold $145,024 worth of shares (3,302 units at $43.92) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,200 worth of shares (200 units at $41.00) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,000 worth of shares (200 units at $40.00) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Financial Officer Jones Cecilia converted options into 7,472 shares and sold $134,247 worth of shares (3,651 units at $36.77), increasing direct ownership by 13% to 33,870 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Principal Accounting Officer Washburn Theodore James Jr. sold $315,091 worth of shares (8,546 units at $36.87), decreasing direct ownership by 91% to 868 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,000 worth of shares (200 units at $40.00) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Ballal Rahul D. converted options into 2,302 shares, increasing direct ownership by 23% to 12,414 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Smith Cynthia converted options into 2,302 shares, increasing direct ownership by 23% to 12,414 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Executive Officer Goff Brian converted options into 22,691 shares and sold $406,487 worth of shares (11,085 units at $36.67), increasing direct ownership by 10% to 123,528 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Scadden David exercised 1,400 shares at a strike of $18.09 and sold $56,000 worth of shares (1,400 units at $40.00) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah exercised 11,914 shares at a strike of $25.01 and sold $452,601 worth of shares (11,914 units at $37.99) (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Director Backstrom Jay T.4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah converted options into 8,374 shares and sold $139,789 worth of shares (4,091 units at $34.17), increasing direct ownership by 8% to 61,271 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Legal Officer Burns James William converted options into 6,000 shares and sold $93,878 worth of shares (2,799 units at $33.54), increasing direct ownership by 13% to 28,650 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah converted options into 6,000 shares and sold $97,568 worth of shares (2,909 units at $33.54), increasing direct ownership by 6% to 56,988 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Financial Officer Jones Cecilia sold $59,701 worth of shares (1,780 units at $33.54) and converted options into 6,000 shares, increasing direct ownership by 16% to 30,049 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Commercial Officer Milanova Tsveta converted options into 6,000 shares and sold $92,906 worth of shares (2,770 units at $33.54), increasing direct ownership by 14% to 26,122 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Executive Officer Goff Brian converted options into 38,277 shares and sold $627,198 worth of shares (18,700 units at $33.54), increasing direct ownership by 21% to 111,922 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Ballal Rahul D. converted options into 2,120 shares, increasing direct ownership by 27% to 10,112 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Capello Jeffrey D converted options into 2,120 shares, increasing direct ownership by 54% to 6,073 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Foster-Cheek Kaye I converted options into 2,120 shares, increasing direct ownership by 40% to 7,468 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Fouse Jacqualyn A converted options into 2,120 shares, increasing direct ownership by 1% to 151,340 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Ho Maykin converted options into 2,120 shares, increasing direct ownership by 14% to 17,032 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Owen Adams Catherine converted options into 2,120 shares, increasing direct ownership by 54% to 6,073 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Scadden David converted options into 2,120 shares, increasing direct ownership by 14% to 17,603 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Smith Cynthia converted options into 2,120 shares, increasing direct ownership by 27% to 10,112 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Capello Jeffrey D converted options into 1,977 shares, increasing direct ownership by 100% to 3,953 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Owen Adams Catherine converted options into 1,977 shares, increasing direct ownership by 100% to 3,953 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Director Fouse Jacqualyn A converted options into 15,933 shares and sold $194,172 worth of shares (7,497 units at $25.90), increasing direct ownership by 6% to 149,220 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SEC Form 4 filed by Chief Corp Dev & Strategy Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Legal Officer Burns James William converted options into 13,500 shares and sold $142,338 worth of shares (4,005 units at $35.54), increasing direct ownership by 60% to 25,449 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Financial Officer Jones Cecilia converted options into 7,667 shares and sold $80,854 worth of shares (2,275 units at $35.54), increasing direct ownership by 26% to 25,829 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Commercial Officer Milanova Tsveta converted options into 5,667 shares and sold $59,743 worth of shares (1,681 units at $35.54), increasing direct ownership by 21% to 22,892 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Executive Officer Goff Brian converted options into 26,500 shares and sold $460,136 worth of shares (12,947 units at $35.54), increasing direct ownership by 17% to 92,345 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Chief Medical Officer Gheuens Sarah converted options into 13,500 shares and sold $142,338 worth of shares (4,005 units at $35.54), increasing direct ownership by 21% to 53,897 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- Principal Accounting Officer Washburn Theodore James Jr. converted options into 5,577 shares and sold $58,819 worth of shares (1,655 units at $35.54), increasing direct ownership by 71% to 9,414 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)